Healthcare Services

One of the Major Drivers of the Primary Biliary Cholangitis Market Is the Surge In Liver Cancer Cases Fuels Growth In Primary Biliary Cholangitis Market

April 6, 2026April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Primary Biliary Cholangitis Market During The Forecast Period 2026–2030?

The market for primary biliary cholangitis has experienced robust expansion in recent years. This market is projected to expand from $1.06 billion in 2025 to $1.15 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 8.4%. Historical growth in this sector is largely due to factors such as a deeper comprehension of autoimmune liver conditions, enhanced access to diagnostic evaluations, the proliferation of specialized liver clinics, increasing clinical recognition of pbc symptoms, and the establishment of conventional pharmacological therapies.

The market size for primary biliary cholangitis is projected to exhibit robust growth over the coming years, reaching $1.6 billion by 2030 at a compound annual growth rate (CAGR) of 8.7%. This expansion during the forecast period is driven by factors such as increasing investments in rare disease research, the rising embrace of personalized medicine strategies, the growth of advanced imaging diagnostics, an expanding pipeline of targeted therapies, and a greater emphasis on early-stage disease management. Notable trends for the forecast period include a heightened focus on targeted drug therapies, the growing adoption of sophisticated diagnostic imaging techniques, an increasing integration of biomarker-based disease monitoring, the broadening of personalized treatment approaches, and an enhanced commitment to early disease detection.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp

Which Major Factors Are Driving The Expansion Of The Primary Biliary Cholangitis Market?

The increasing incidence of liver cancer is projected to stimulate the expansion of the primary biliary cholangitis market. Liver cancer is defined as a form of cancer that originates within the liver’s cells. The importance of primary biliary cholangitis in relation to liver cancer is considerable, stemming from its heightened risk for various malignancies, including cholangiocarcinoma and hepatocellular carcinoma. The expanding prevalence of this condition and its potential health issues contribute to the development of the primary biliary cholangitis market. As an illustration, in January 2024, the American Cancer Society, a major professional group in the U.S., forecast roughly 41,630 new diagnoses of liver cancer across the country, with 28,000 cases affecting men and 13,630 women. Moreover, around 29,840 people (19,120 men and 10,720 women) are anticipated to die from this disease. Thus, the escalation in liver cancer acts as a key driver for the primary biliary cholangitis market’s growth.

What Market Segments Are Evaluated Within The Primary Biliary Cholangitis Market?

The primary biliary cholangitis market covered in this report is segmented –

1) By Treatment Type: Drugs, Liver Transplantation

2) By Diagnosis: Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses

3) By End-Users: Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Drugs: Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Immunosuppressive Drugs, Other Targeted Therapies

2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT), Living Donor Liver Transplantation, Hepatobiliary Surgery For Liver Transplant

What Trends Are Projected To Affect The Primary Biliary Cholangitis Market?

Leading companies within the primary biliary cholangitis market are concentrating on creating novel and specialized therapeutic options, including orphan drugs that combine obeticholic acid (OCA) and bezafibrates for the treatment of primary biliary cholangitis (PBC), seeking to secure exclusive market positions. This combination of OCA and bezafibrate, having received an orphan drug designation, is intended to provide a more holistic and impactful method for handling PBC treatment, with the potential to enhance the quality of life for those living with this uncommon illness. An illustrative example is Intercept Pharmaceuticals, Inc., a a US-based biopharmaceutical firm, which obtained orphan drug designation from the FDA in May 2023 for its combination therapy of obeticholic acid (OCA) and bezafibrate, identified as a PPAR agonist, as a prospective therapy for primary biliary cholangitis (PBC), which is a progressive liver condition; notably, obeticholic acid itself (known commercially as Ocaliva) is already approved for PBC in the US.

Who Are The Top Market Participants Influencing The Primary Biliary Cholangitis Market?

Major companies operating in the primary biliary cholangitis market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck And Co Inc, Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc, Dr Reddys Laboratories Ltd, Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, Intercept Pharmaceuticals Inc, Arrowhead Pharmaceuticals Inc, Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc, Albireo Pharma Inc, Genfit SA, CymaBay Therapeutics Inc, Ascletis Pharma Inc, Ipsen Pharma, Ferring Pharmaceuticals

Read the full primary biliary cholangitis market report here:

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

Which Region Currently Holds The Largest Share Of The Primary Biliary Cholangitis Market?

North America was the largest region in the primary biliary cholangitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Primary Biliary Cholangitis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13520&type=smp

Browse Through More Reports Similar to the Global Primary Biliary Cholangitis Market 2026, By The Business Research Company

Polyclonal Antibodies Global Market Report

https://www.thebusinessresearchcompany.com/report/polyclonal-antibodies-global-market-report

Diagnostic Specialty Antibodies Global Market Report

https://www.thebusinessresearchcompany.com/report/diagnostic-specialty-antibodies-global-market-report

Next Generation Antibody Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795